Resistance in Hematologic Malignancies and Cancer

Description

English | 2025 | PDF | 11 MB | 311 Pages

Lucia Messingerova, Albert Breier, B0DLN3VJBG, 0443217912, 0443217904, 9780443217906, 978-0443217906, 978-0-443-21790-6, 9780443217913, 978-0443217913

Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies. Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research. It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells. By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise

• Describes the different mechanisms of resistance; cooperation in net resistance to antileukemic drugs
• Provides hallmark information about cell regulation pathways in drug resistance development
• Brings information about causes of drug resistance in leukemia and hematologic malignancies including lymphoma and myeloma